Skip to main content

Table 4 Logistic regression analysis to identify patients harboring the T790M substitution among those with EGFR-mutated lung cancer (n = 53)

From: Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Variables Univariate Analyses Multivariate Analysis
OR 95%CI P-value OR 95%CI P-value
Mutation site at initial diagnosis; Exon 19 Deletion vs. L858R 0.17 0.05–0.51 0.002 0.04 0.004–0.34 0.003
Reason for termination of TKIs; 2.26 1.25–4.11 0.007 3.65 1.39–9.59 0.008
Ongoing Reference Reference
AEs 1 1
Tumor growth 37.3 3.30–421.6 0.003 33.8 1.60–713.3 0.024
New lesions 12.4 1.32–117.0 0.027 44.9 2.13–950.9 0.014
Medical Drugs at TKI-naïve line 0.24 0.08–0.72 0.01 0.09 0.01–0.62 0.014
Gefitinib Reference Reference
Erlotinib 0.18 0.035–0.95 0.044 0.49 0.02–0.99 0.049
Afatinib 0.06 0.007–0.55 0.012 0.01 0.0002–0.53 0.02
Chemotherapy; absent vs. present 2.63 0.84–8.22 0.09 NI
“Serum level of CEA at progression” divided by “Serum nadir level of CEA” 1.16 0.97–1.39 0.11 1.22 0.77–1.93 0.4
Serum nadir level of CEA (ng/mL) 0.97 0.95–1.01 0.14 NI
  1. Abbreviations: OR Odds ratio; CI confidence interval; TKI tyrosine kinase inhibitor; AEs adverse effects; CEA carcinoembryonic antigen; Variables with a p-value < 0.15 on univariate analysis were entered into multivariate logistical analysis by a simultaneous method. NI, not included in the best multivariate logistic regression model